 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
Adding Infliximab to the Treatment Regimen for Giant Cell Arteritis
1 May 2007 | Volume 146 Issue 9 | Page I-12
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
The summary below is from the full report titled "Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis. A Randomized Trial." It is in the 1 May 2007 issue of Annals of Internal Medicine (volume 146, pages 621-630). The authors are G.S. Hoffman, M.C. Cid, K.E. Rendt-Zagar, P.A. Merkel, C.M. Weyand, J.H. Stone, C. Salvarani, W. Xu, S. Visvanathan, and M.U. Rahman, for the Infliximab-GCA Study Group.
What is the problem and what is known about it so far?
Giant cell arteritis (GCA, also called temporal arteritis) involves inflammation of large and medium-sized arteries (vasculitis). This condition occurs in elderly people and can lead to sudden blindness. Prompt treatment can prevent blindness. Standard therapy for GCA consists of large doses of steroid drugs (such as prednisone), followed by a gradual decrease in the dose. Patients may need to take a low dose of steroid for many years. Unfortunately, in many patients, symptoms (including muscle ache, fatigue, headache, and change in vision) return as the dose is lowered, or side effects from the steroid develop. Thus, we need better ways to treat GCA. Infliximab is a drug that blocks an inflammatory chemical (called tumor necrosis factor, or TNF) of the immune system. There is evidence that TNF plays a role in GCA. Earlier reports in small numbers of patients have suggested that blocking the effects of TNF may decrease the amount of steroid needed to treat GCA.
Why did the researchers do this particular study?
To find out whether treatment with infliximab improved outcomes for people with GCA.
Who was studied?
44 patients with newly diagnosed GCA who had responded to steroid treatment.
How was the study done?
The researchers assigned patients at random to receive an intravenous dose of either infliximab or a placebo (a substance that looked like infliximab but contained no active ingredient) at the start of the study; after 2, 6, and 8 weeks; and then every 8 weeks after that. All patients followed a schedule to slowly decrease the steroid dose. If symptoms returned, patients would need to increase the steroid dose and start to decrease the amount they received all over again. The researchers collected information on whether patients' symptoms returned (called relapse) and on steroid dose over the course of the study. The researchers planned for the study to last 54 weeks.
What did the researchers find?
Although the study was supposed to continue for 54 weeks, the researchers stopped it after 22 weeks because infliximab did not appear to benefit patients in terms of preventing relapse of symptoms or reducing the amount of steroids required for treatment.
What were the limitations of the study?
The study was small and stopped early, so the researchers could not rule out a small benefit of infliximab. The study was also too small and brief to provide extensive information on the side effects of infliximab.
What are the implications of the study?
Infliximab is unlikely to benefit patients with newly diagnosed GCA.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  C. De Silva, R. Stevens, and K. M. Jordan Inflammatory aortitis controlled by the Chinese herbal remedy Donglingcao Pian Rheumatology, August 1, 2008; 47(8): 1257 - 1259. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Seton, M. Pless, J. A. Fishman, P. A. Caruso, and E. T. Hedley-Whyte Case 18-2008 -- A 68-Year-Old Man with Headache and Visual Changes after Liver Transplantation N. Engl. J. Med., June 12, 2008; 358(24): 2619 - 2628. [Full Text] [PDF]
|
|
|
|
 |
|
 H. L. Gornik and M. A. Creager Aortitis Circulation, June 10, 2008; 117(23): 3039 - 3051. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Tato and U. Hoffmann Giant cell arteritis: a systemic vascular disease Vascular Medicine, May 1, 2008; 13(2): 127 - 140. [Abstract] [PDF]
|
|
|
|
 |
|
 C. Salvarani, N. Pipitone, L. Boiardi, and G. G Hunder Do we need treatment with tumour necrosis factor blockers for giant cell arteritis? Ann Rheum Dis, May 1, 2008; 67(5): 577 - 579. [Full Text] [PDF]
|
|
|
|
|
|
V M Martinez-Taboada, V Rodriguez-Valverde, L Carreno, J Lopez-Longo, M Figueroa, J Belzunegui, E M Mola, and G Bonilla A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects Ann Rheum Dis, May 1, 2008; 67(5): 625 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Arkfeld How Is Infliximab Harmful? Ann Intern Med, January 15, 2008; 148(2): 166 - 166. [Full Text] [PDF]
|
|
|
|
|
|
C. Salvarani and G. G. Hunder Tumor Necrosis Factor Blocking Agents in Polymyalgia Rheumatica and Giant Cell Arteritis Ann Intern Med, January 15, 2008; 148(2): 167 - 168. [Full Text] [PDF]
|
|
|
|
|
|
D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii2 - iii22. [Full Text] [PDF]
|
|
|
|
 |
|
 CARPHOLOGY BY Rajendra Practical Neurology, August 1, 2007; 7(4): 276 - 276. [Full Text] [PDF]
|
|
|
|
|
|
R. Luqmani Treatment of Polymyalgia Rheumatica and Giant Cell Arteritis: Are We Any Further Forward? Ann Intern Med, May 1, 2007; 146(9): 674 - 676. [Full Text] [PDF]
|
|
Read all Rapid Responses
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
